EXONATE LTD has a total of 20 patent applications. It increased the IP activity by 600.0%. Its first patent ever was published in 2013. It filed its patents most often in United Kingdom, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are HUBEI BIO PHARMACEUTICAL IND TECHNOLOGICAL INST INC, MNEMOSYNE PHARMACEUTICALS INC and PRESIDIO PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Australia | 3 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | United States | 2 | |
#7 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Morris Jonathan | 15 |
#2 | Morley Andrew David | 11 |
#3 | Bates David | 7 |
#4 | Baxter Andrew Douglas | 6 |
#5 | Toop Hamish | 6 |
#6 | Batson Jennifer | 6 |
#7 | Harper Steven James | 2 |
#8 | Gammons Melissa | 2 |
#9 | Bates David Owen | 2 |
Publication | Filing date | Title |
---|---|---|
GB202010829D0 | Compounds for treatment of neovascular diseases | |
GB201912449D0 | Compounds for treatment of neovascular diseases | |
US2020270249A1 | Srpk1 inhibitors | |
GB201810765D0 | SRPK1 inhibitors | |
GB201715637D0 | SRPK1 Inhibitors | |
GB201518365D0 | Compounds | |
EP2908811A1 | Compounds useful for treating ocular neovascularisation |